Start here if you're new
what it is
Ovid is a 23-person biotech chasing seizure and brain-disease drugs.
how it gets paid
Last year Ovid Therapeutics made $566K in revenue.
what just happened
Ovid printed $7M in quarterly revenue, while EPS stayed at -$0.24.
At a glance
C balance sheet — red flag territory — real financial stress
10/100 earnings predictability — expect surprises
68.3% return on capital — a money-printing machine
-$0.37 fy2024 eps est
$1M fy2024 rev est
xvary composite: 19/100 — weak
What they do
Ovid is a 23-person biotech chasing seizure and brain-disease drugs.
Ovid's moat is thin, but it exists. The company has 3 novel drug methods, and that is better than one molecule and worse than a real product portfolio. With 23 employees, your money funds science, not a sales army. That is the whole bet.
How they make money
$566K
annual revenue
total revenue
$566K
n/a
The products that matter
clinical-stage drug candidate
OV329
lead asset · valuation driver
this is the asset doing the heavy lifting for a company valued at ~$256M with just $6.61M in trailing revenue. If OV329 works, the story survives. If it stumbles, the current valuation has very little else to lean on.
pipeline hinge
preclinical and research programs
Pipeline assets
early stage · cash consuming
these programs matter because there is no approved product offsetting development risk. With cash runway only through mid-2026, every program competes for limited funding.
option value
collaboration economics
Partner revenue
$5.3M · most of trailing revenue
collaboration revenue contributed $5.3M versus $1.31M from other revenue. That's why reported sales exist at all — and why they can swing hard from period to period.
80% of trailing revenue
Key numbers
$256M
market cap
You are paying $256M for a company with $566K in annual revenue. The gap is the story.
$566K
annual revenue
EDGAR shows $566K for the year, while the latest quarter printed $7M. That is a lumpy business, not a smooth one.
$175M
private raise
The October 2025 financing can reach $175M. That is 68% of market cap, so dilution is not a side note.
$12M
long-term debt
Debt is only $12M, or 5% of capital. That means the balance sheet is not the biggest problem here.
Financial health
C
strength
- balance sheet grade C — very weak — significant financial distress
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $12M (5% of capital)
C — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for OVID right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Ovid printed $7M in quarterly revenue, while EPS stayed at -$0.24.
Revenue was up 4,850% vs. prior year, but the base was tiny. EDGAR shows $566K in annual revenue, while Yahoo Finance lists $566.0B TTM revenue, which conflicts with the SEC data, so EDGAR wins.
$7.0M
revenue
$0.24
eps
n/a
operating margin
the number that mattered
The $7M quarter mattered because it was more than 12 times the $566K annual base in EDGAR.
source: EDGAR SEC filing, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk here is cash depletion by mid-2026. For Ovid, funding risk is not a background detail — it sits right in the middle of the equity story.
high
cash runway depletion
Management stated existing cash will not be sufficient to fund operations beyond mid-2026. That means dilution, debt, or a partnership likely moves from theory to necessity within the next few quarters.
direct exposure: the balance sheet funds 100% of the current pipeline effort
high
clinical trial failure for OV329
OV329 is the lead asset and the main reason investors tolerate a 19.7x price-to-sales multiple on $6.61M of trailing revenue. If the data disappoints, the stock loses the narrative supporting its valuation.
valuation at risk: a ~$256M market cap with no approved product has little cushion
med
revenue concentration in collaboration payments
Collaboration revenue was $5.3M versus $1.31M of other revenue. That's roughly an 80/20 split. If those payments slow or disappear, reported revenue can fall back fast.
revenue exposure: about 80% of trailing revenue sits in one bucket
med
NASDAQ minimum bid pressure
The stock has a compliance period through February 9, 2026. With shares at $1.56 and a 52-week range of $0–$2, the exchange issue is not hypothetical.
possible outcome: reverse split, prolonged volatility, or delisting pressure
A funding event before or around mid-2026 would hit the same shareholders already underwriting clinical risk, revenue concentration, and listing pressure.
source: institutional data · regulatory filings · risk analysis
Pay attention to
funding risk
mid-2026 cash runway
Management says existing cash does not get the company past mid-2026. That makes financing the key near-term variable.
clinical catalyst
OV329 Phase 1 data
The next readout is expected in H2 2026. For a company this early, data is strategy.
listing watch
February 9, 2026 compliance deadline
If the stock cannot stay clear of the $1 bid issue, the company may need a reverse split or another fix.
leadership
new CEO, new capital priorities
Meg Alexander assumes the CEO role on January 1, 2026. Watch for any change in pipeline focus, partnering strategy, or spending pace.
Analyst rankings
earnings predictability
10 / 100
In human-speak: analysts do not trust this revenue and earnings stream to repeat cleanly. That's normal for a company living on milestone-style payments and R&D spend.
risk profile
5 / 100 price stability
The stock has traded with almost no stability. You should expect sharp moves around data, financing, and listing headlines.
source: institutional data
Institutional activity
institutional ownership data for OVID is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive